Literature DB >> 8598645

Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients.

V Leuzzi1, G Trasimeni, G F Gualdi, I Antonozzi.   

Abstract

Brain magnetic resonance imaging (MRI) was performed in 17 late-detected PKU patients (aged 2.8-25 years). Twelve subjects had been treated late (0.7-4.5 years), and 5 not at all. Four were still on diet when the study was performed. Mental development was normal in 4 subjects, mildly retarded in 6, and moderately or severely retarded in 7. None had exhibited mental or neurological deterioration. On MRI examination a symmetrical increase of T2-weighted signal in the periventricular white matter was found in all patients, although to different degrees. Concomitant signal decrease on the T1-weighted sequences was detected in 9 patients. Ten subjects showed focal white-matter abnormalities. A variable degree of cortical and subcortical atrophy was found in 12 subjects, and asymmetry of lateral ventricles in 4. White-matter involvement correlated with phenylalanine concentrations during the year preceding (rs = 0.5706; p < 0.02) and at the time of (rs = 0.6182, p < 0.01) the investigation. Cortical and subcortical atrophy correlated with the patient's age (rs = 0.5889, p < 0.02, and rs = 0.5929, p < 0.02, respectively). We conclude that late-detected PKU patients showed the same MRI abnormalities reported in early-treated subjects and in subjects who underwent neurological deterioration; white-matter abnormalities possibly result from the recent exposure to high phenylalanine concentrations; in late-detected PKU subjects cerebral atrophy could be the late result of chronic exposure to high phenylalanine concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8598645     DOI: 10.1007/bf02436009

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  Computed tomography ventricular size has no predictive value in diagnosing pseudotumor cerebri.

Authors:  D M Jacobson; P N Karanjia; K A Olson; J J Warner
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

2.  The development of auditory and visual evoked potentials in early treated phenylketonuric children.

Authors:  F Cardona; V Leuzzi; I Antonozzi; P Benedetti; A Loizzo
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1991 Jan-Feb

3.  Spasticity and white matter abnormalities in adult phenylketonuria.

Authors:  P A McCombe; D B McLaughlin; J B Chalk; N N Brown; J J McGill; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

4.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Clinicopathologic correlations of cranial magnetic resonance imaging of periventricular white matter.

Authors:  D Leifer; F S Buonanno; E P Richardson
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

6.  Phenylalanine and phenylacetate adversely affect developing mammalian brain neurons.

Authors:  K F Swaiman; S R Wu
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

7.  Magnetic resonance imaging of the brain in phenylketonuria.

Authors:  M A Cleary; J H Walter; J E Wraith; J P Jenkins; S M Alani; K Tyler; D Whittle
Journal:  Lancet       Date:  1994-07-09       Impact factor: 79.321

8.  Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging.

Authors:  M I Chimowitz; M L Estes; A J Furlan; I A Awad
Journal:  Arch Neurol       Date:  1992-07

9.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

10.  Golgi-Kopsch silver study of the brain of a patient with untreated phenylketonuria, seizures, and cortical blindness.

Authors:  S Kornguth; E Gilbert-Barness; E Langer; L Hegstrand
Journal:  Am J Med Genet       Date:  1992-11-01
View more
  10 in total

1.  Characterization of tremor in phenylketonuric patients.

Authors:  Belén Pérez-Dueñas; Josep Valls-Solé; Emilio Fernández-Alvarez; Jaon Conill; Maria Antonio Vilaseca; Rafael Artuch; Jaume Campistol
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

2.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

3.  Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.

Authors:  V Leuzzi; M C Bianchi; M Tosetti; C L Carducci; C A Carducci; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

4.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

5.  Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion.

Authors:  T Scarabino; T Popolizio; M Tosetti; D Montanaro; G M Giannatempo; R Terlizzi; S Pollice; A Maiorana; N Maggialetti; A Carriero; V Leuzzi; U Salvolini
Journal:  Radiol Med       Date:  2009-03-10       Impact factor: 3.469

6.  Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria.

Authors:  Renzo Manara; Alessandro P Burlina; Valentina Citton; Mario Ermani; Francesco Vespignani; Carla Carollo; Alberto B Burlina
Journal:  Neuroradiology       Date:  2009-08-04       Impact factor: 2.804

7.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

Review 8.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

9.  Can untreated PKU patients escape from intellectual disability? A systematic review.

Authors:  Danique van Vliet; Annemiek M J van Wegberg; Kirsten Ahring; Miroslaw Bik-Multanowski; Nenad Blau; Fatma D Bulut; Kari Casas; Bozena Didycz; Maja Djordjevic; Antonio Federico; François Feillet; Maria Gizewska; Gwendolyn Gramer; Jozef L Hertecant; Carla E M Hollak; Jens V Jørgensen; Daniela Karall; Yuval Landau; Vincenzo Leuzzi; Per Mathisen; Kathryn Moseley; Neslihan Ö Mungan; Francesca Nardecchia; Katrin Õunap; Kimberly K Powell; Radha Ramachandran; Frank Rutsch; Aria Setoodeh; Maja Stojiljkovic; Fritz K Trefz; Natalia Usurelu; Callum Wilson; Clara D van Karnebeek; William B Hanley; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2018-08-29       Impact factor: 4.123

10.  Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency.

Authors:  Amelie S Lotz-Havla; Katharina Weiß; Katharina Schiergens; Stephanie Regenauer-Vandewiele; Klaus G Parhofer; Tara Christmann; Luise Böhm; Joachim Havla; Esther M Maier
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.